New inhaled insulin could hold promise for people with diabetes
Afrezza is manufactured by pharmaceutical company MannKind Corp. According to their vice-preident of pharmaceutical development, Andrea Leone-Bay: "Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body."
MannKind were quick to distinguish Afrezza from Exubera, both in terms of manufacture and function. The diabetes treatment is inhaled as a dry powder, and starts acting immediately, reaching its peak within 12 to 15 minutes.
Also related to this storyDiabetes forum
Blood sugar symptoms
Diabetes donate to charity
The Diet Plate for People with Diabetes
Diabetes.co.uk ID alert wristband
Diabetes pensions and annuities
Insulin Dependent Diabetes Trust call for greater awareness
Diabetes company starts oral insulin trials
Cardiovascular Risk linked with insulin resistance in type 1 diabetes
Sanofi maintain diabetes drug no riskier than insulin
News presenter happy with insulin pump
Vitamins linked to insulin and diabetes
New stem cell treatment for diabetes could replace insulin